COSRX Six Peptide review: a count is not a copper concentration

The booster’s full name limits the review

The captured heading names The 6 Peptide Skin Booster Serum. The manufacturer also uses “1 serum, 6 peptides” and six-peptide-complex language. Those descriptions identify the particular booster record, rather than six separately reviewed finished products.

The count belongs to the company’s description of the mixture. It does not specify an application quantity, the fraction of the bottle occupied by peptide material or the share assigned to copper. Keeping the exact name attached makes the later laboratory claims easier to locate without treating a broad peptide category as the studied preparation.

Copper is one named entry in the declaration

Copper Tripeptide-1 appears in the complete captured list, together with five other peptide names and additional formulation ingredients. The manufacturer declaration supports saying that a copper-named peptide is declared. It does not establish equal quantities of the six entries or disclose an assayed copper mass fraction.

Six names do not mean six percent, and a six-peptide complex does not reveal each constituent’s amount. The Mary&May review supplies a separate record for exploring another count question. Similar counts are a reason to read the definitions carefully, not an assumption that the mixtures are quantitatively equivalent.

The list cannot be converted into a split

The serum’s ingredient sequence provides names without an individual numerical allocation. Estimating that allocation from position would require information not supplied by the examined record. No purity, supplier dilution or copper-assay method is established by these passages.

FDA’s US cosmetic labeling explanation describes ordering qualifications, including the option to list ingredients at no more than one percent in any order after higher-concentration ingredients. That framework explains why a sequence alone is insufficient; it does not determine this named product’s exact quantities or deliver a compliance judgment. The grade-and-purity guide develops the separate specification question.

Large percentages refer to different reported endpoints

The manufacturer reports +162.5% deep moisture, +76.4% skin texture, +40.1% clarity, +24.5% radiance and +22.2% density. These are the endpoint labels in the saved result panel. They are not five ingredient concentrations and cannot be added into a copper strength figure.

Nor should the largest number be substituted for a wrinkle finding or a claim that every participant changed by that amount. The examined panel does not supply the complete endpoint definitions, individual distributions or calculation methods. Keeping each label beside its figure prevents a dramatic-looking percentage from becoming a different claim than the one reported.

Twenty subjects is a study qualifier, not a guarantee

The panel attributes its figures to clinical trials of twenty subjects at Dermacosmetic Skin Science Laboratory Co., Ltd., dated September 18 to October 31, 2023. Those details belong to the manufacturer summary. The date range identifies the stated study period, not a promised duration of results for a reader.

This review did not obtain the complete laboratory report, inspect control conditions or determine how each measure was collected. The study-endpoint article explains why a population and an outcome need their own methods. A laboratory name and a headcount make a claim more locatable without making all those details available.

The five percentages do not have a disclosed common baseline or unit that makes them directly comparable to one another. A larger reported moisture change cannot be called a larger density change, and neither can be assigned to the copper ingredient alone. The short summary also does not show whether each figure was calculated in the same way. These are limits on interpretation of the public panel, rather than a finding that the laboratory did not conduct the stated work.

A finished-serum result does not isolate copper

The product combines the named peptides with other ingredients. The same official source does not establish a comparison isolating Copper Tripeptide-1’s contribution to the reported results in the examined passages. A result attributed to the booster therefore should not be rewritten as a numerical copper-only effect.

The absence of that comparison here does not demonstrate that copper has no contribution. It limits what the supplied evidence can attribute. For a different advertised constituent-percentage question, the Peach & Lily review offers further reading. Its record cannot supply the missing quantities or laboratory methods for COSRX.

The count and the outcomes can stay informative

The defensible account retains the booster identity, its six-peptide description, its declared copper name and the qualified endpoint summary. It leaves the constituent amounts and underlying study methods unresolved. That is a useful reading of the manufacturer record, without pretending it provides a potency scale.

The original source comparison separates other kinds of product numbers. Linking these records does not make their endpoints or ingredient systems interchangeable. The useful question is what each number measures, rather than which page displays the largest one. No comparative clinical conclusion follows from the peptide count or the five result percentages alone.